List of Olux E drug patents

Olux E is owned by Mylan.

Olux E contains Clobetasol Propionate.

Olux E has a total of 2 drug patents out of which 0 drug patents have expired.

Olux E was authorised for market use on 12 January, 2007.

Olux E is available in aerosol, foam;topical dosage forms.

Olux E can be used as treatment of corticosteroid-responsive dermatoses.

The generics of Olux E are possible to be released after 05 November, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962000 MYLAN Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(2 years from now)

US8460641 MYLAN Microemulsion process and composition
Nov, 2028

(5 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 12 January, 2007

Treatment: Treatment of corticosteroid-responsive dermatoses

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of OLUX E before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in